Medicare has introduced a pilot program aimed at increasing access to certain medications. The program focuses on GLP-1 drugs, which are now being made more accessible to participants. The pilot program has a defined duration, set to run from the beginning of July 2026 to the end of December 2027.

This timeframe suggests a nearly 18-month trial period for the program. Further details about the program, including its goals and eligibility criteria, can be found through Medicare or news sources such as KXAN, which initially reported on the initiative.